Therapeutic areas and Protocols
Infectology
Active Studies - Infectology
C5091017
Protocol C5091017: A Phase 3, Double-Blind, 2-Arm Efficacy and Safety Interventional Study to Investigate Orally Administered Ibuzatrelvir Compared to Placebo in Symptomatic Adult and Adolescent Non-Participants Hospitalized with COVID-19 Who Are at High Risk of Progressing to Severe Disease
Completed Studies - Infectology
OTAC INSIGHT 012
INSIGHT 012
"Ensayo internacional multicéntrico, aleatorizado, doble ciego y controlado con placebo sobre la seguridad y la eficacia de la inmunoglobulina hiperinmune intravenosa anti coronavirus para el tratamiento de pacientes adultos ambulatorios en estadios tempranos de la COVID-19"
RECLAIM
“Un estudio multicéntrico, aleatorizado, doble ciego de Fase 3 para evaluar la seguridad y eficacia de contezolida acefosamil y contezolida en comparación con linezolida administrado por vía intravenosa y oral a adultos con infecciones moderadas o severas del pie diabético”
VOLITION
A study to evaluate the efficacy, safety, participant choice, and preference of a once-daily oral regimen or a bimonthly long-acting injectable regimen for the treatment of HIV-1 in adults not previously taking antiretroviral therapy.
SUNRISE-3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19.
ENANTA
Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938 in non-hospitalized adults with acute Respiratory Syncytial Virus infection and at high risk of complications.
SCORPIO-HR
A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared to Placebo in Non-Hospitalized Participants With COVID-19
BANNER
Estudio abierto, de fase 2a, multicéntrico, aleatorizado, de dos partes, con diseño adaptativo, para evaluar el efecto antiviral, la seguridad y la tolerabilidad de GSK3810109A, un anticuerpo monoclonal humano ampliamente neutralizante específico del VIH-1 en adultos infectados por el VIH-1 sin tratamiento previo con antirretrovirales.
TACKLE
"Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para determinar la seguridad y eficacia de AZD7442 para el tratamiento de COVID-19 en adultos no hospitalizados"
Obesity
Estudios Activos - Obesidad
Enith 1
WC45725 (0165/1297): PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY.
GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY ADMINISTRATION RO7795068 (CT-388) TO OVERWEIGHT OR OBESE PARTICIPANTS WITHOUT TYPE 2 DIABETES
Estudios Finalizados - Obesidad
SYNCHRONIZE
A Phase III, Randomized, Double-Blind, Parallel-Group, Event-Driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared to Placebo in Participants With Overweight or Obesity
SURMOUNT
A Phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of Tirzepatide in reducing morbidity and mortality in adults with obesity. This study will investigate the effect of tirzepatide on reducing morbidity and mortality in adults living with obesity and will provide additional evidence of the potential clinical benefits of tirzepatide in this population.
Rheumatology
Active Studies - Rheumatology
WA45846
A PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO7790121 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO OR INTOLERANCE OF TNF AND/OR JAK INHIBITORS
BE-EARLY
219240
“A phase 4, multicenter, prospective, open-label study describing the efficacy and safety of subcutaneously administered belimumab in adult participants with early-stage systemic lupus erythematosus”
EMERALD
"A long-term, multicenter, randomized, blinded, phase 3 extension study to evaluate the safety and efficacy of BIIB059 in adult participants with active systemic lupus erythematosus (SLE)"
Completed Studies - Rheumatology
ARGX-113-2306
Ensayo clínico de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, con una extensión abierta para evaluar la eficacia, seguridad y tolerabilidad de Efgartigimod PH20 administrado por vía subcutánea mediante jeringa precargada en pacientes adultos con enfermedad de Sjögren primaria (ARGX-113-2306)
MK 6194-006
"Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de MK-6194 en participantes adultos con lupus eritematoso sistémico."
APATURA
DRI17821
Un estudio de fase 2, aleatorizado, doble ciego, controlado con placebo, de rango de dosis, eficacia y seguridad de SAR441566 más metotrexato en adultos con artritis reumatoide de moderada a grave.
JASMINE 80202135SLE2001
Phase 2, multicenter, randomized, double-blind, placebo-controlled study of nipocalimab in subjects with active systemic lupus erythematosus (SLE).
VITALISSCE
”Estudio de Fase II, aleatorizado, controlado con placebo, doble ciego, de grupos paralelos, para evaluar la eficacia y la seguridad de, al menos, 48 semanas de tratamiento con BI 685509 oral en adultos con esclerosis sistémica progresiva”
MARS-17
Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis (MARS-17) de GSK3858279 en participantes adultos con dolor moderado a severo ocasionado por artrosis de rodilla.
WILLOW LTE MS200569_0048
Un estudio de fase II, doble ciego, de dosis variable, paralelo y de extensión a largo plazo para evaluar la seguridad y la eficacia de Enpatoran en participantes con lupus eritematoso cutáneo subagudo, lupus eritematoso discoide y/o lupus eritematoso sistémico que han completado el tratamiento del estudio WILLOW (MS200569_0003)
Pediatrics
Estudios Activos - Pediatría
There are no active studies at this time
Estudios Finalizados - Pediatría
LIBELULA
Debio 4326 HAB97073
"Estudio Fase III, multicéntrico, abierto, de un solo brazo; sobre eficacia, seguridad y farmacogenética de Debio 4326, una formulación de liberación prolongada de 70mg de acetato de triptorelina, en participantes pediátricos que reciben tratamiento liberador de gonadotropina- Terapia de agonía hormonal para la pubertad precoz central."
Osteoporosis
Active Studies - Osteoporosis
There are no active studies at this time
Completed Studies - Osteoporosis
ARTEMIS
Estudio de fase 2, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de determinación de dosis para evaluar la seguridad, la tolerabilidad y la eficacia de AGA2118 en mujeres posmenopáusicas con baja densidad mineral ósea.
Oncology
Active Studies - Oncology
DESTINY-Endometrial02 (DE-02)
Full protocol title: Phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan versus standard treatment (carboplatin in combination with paclitaxel) as adjuvant treatment for HER2-expressing endometrial cancer (IHC 3+/IHC2+).
DESTINY
DS8201-724, Multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (Enhertu®) plus chemotherapy plus or less pembrolizumab versus chemotherapy plus trastuzumab plus or less pembrolizumab as first-line treatment in participants with HER2-positive, locally advanced or metastatic unresectable gastric or gastroesophageal junction (GEJ) cancer (DESTINY-Gastric05)
DS7300-203
DS7300-203: An open-label, pan-tumoral phase 2 study to evaluate the efficacy and safety of Ifinatamab Deruxtecan (I-DXD) in subjects with recurrent or metastatic solid tumors.
BNT323-01
Open-label trial of single-agent chemotherapy versus investigator-chosen chemotherapy in previously treated patients with recurrent or metastatic HER2-expressing endometrial cancer
Completed Studies - Oncology
DYNASTY-Breast02
Estudio de fase 3, aleatorizado, multicéntrico y abierto para evaluar DB-1303 en comparación con la quimioterapia elegida por el investigador en pacientes con cáncer de mama metastásico con baja expresión del receptor 2 del factor de crecimiento epidérmico humano (HER2) y con sobreexpresión del receptor hormonal (HR+) cuya enfermedad ha progresado con el tratamiento endocrino (TE) (DYNASTY-Breast02)
OPERA-01
OP-1250-301
“Estudio de fase 3, aleatorizado, de etiqueta abierta, de monoterapia con OP-1250 frente al estándar de atención para el tratamiento del cáncer de mama ER+, HER2- avanzado o metastásico después de la terapia endocrina y con inhibidores CDK4/6 (OPERA-01).”
ZINNIA
20210031
“Un estudio doble ciego, aleatorizado para evaluar la eficacia, la seguridad y la inmunogenia de ABP 206 en comparación con OPDIVO® (Nivolumab) en sujetos con melanoma irresecable o metastásico sin exposición previa al tratamiento”
VERBENA
A randomized, double-blind study to compare the pharmacokinetics, between ABP 206 and Nivolumab (Opdivo®) in subjects with stage III or IV melanoma resected in the adjuvant setting.
TROPION 02
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients With First-Line Inoperable or Metastatic Locally Recurrent Triple-Negative Breast Cancer Who Are Not Candidates for Inhibitor Therapy PD1/PD-L1 (TROPION Mama02)
lidERA/TRIO045
Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared to Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Pulmonology
Active Studies - Pulmonology
CBP-201-207
Chronic Obstructive Pulmonary Disease (COPD)/CBP-201-207
A phase 2, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy and safety of rademikibart as add-on therapy for an acute exacerbation in participants with chronic obstructive pulmonary disease and type 2 inflammation.
ARIA – GSK 206867
Phase 3, 24-week, randomized, double-blind, parallel-group, Bayesian dynamic model study to compare the efficacy, safety, tolerability, and pharmacokinetics of FF/UMEC/VI with that of FF/VI in participants aged 12 to 17 years with inadequately controlled asthma receiving stable maintenance therapy with ICS/LABA.
Completed Studies - Pulmonology
PULSEAIR
Ensayo de eficacia y seguridad de 4 semanas, doble ciego, controlado con placebo y de grupos paralelos de una combinación de propionato de fluticasona/sulfato de albuterol en comparación con propionato de fluticasona, sulfato de albuterol o placebo administrados mediante inhalador de polvo seco multidosis en participantes de 12 años o más con asma.
EXHALE 3
Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad del dexpramipexol administrado por vía oral durante 52 semanas en participantes con asma eosinofílica grave (EXHALE-3)
FLASH
Título: Estudio de fase 2a, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Atuliflapon administrado por vía oral una vez al día durante doce semanas en adultos con asma no controlada de moderada a grave.
EXHALE 2 ARETEIA
AR-DEX-22-01
Un estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad del dexpramipexol administrado por vía oral durante 52 semanas en participantes con asma eosinofílica grave (EXHALE-2)
GB43374 OLE – ALNASA
Phase III multicenter open-label extension (OLE) study to evaluate the long-term safety and efficacy of astegolimab in combination with standard of care (SOC),
FLAIR
FpA-AS-30094“Estudio aleatorizado, doble ciego, multicéntrico, con control activo y con grupos paralelos para evaluar la eficacia y seguridad de la combinación en dosis fijas de propionato de fluticasona/sulfato de albuterol para las exacerbaciones graves del asma en pacientes con asma”
TANGO
Un ensayo de 52 semanas, aleatorizado, doble ciego, multicéntrico, de grupos paralelos de 2 brazos que evalúa la eficacia y seguridad del inhalador de polvo seco (DPI) CHF6001 (dosis diaria total 3200 ug) como complemento al corticosteroide inhalado de dosis media o alta de mantenimiento en combinación con agonistas ß2 de acción prolongada en sujetos con asma no controlada
DOMINICA
Estudio de fase 3 de eficacia y seguridad de benralizumab en pacientes pediátricos con asma eosinofílica grave, tiempo hasta la primera exacerbación del asma, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo
Nephrology
Active Studies - Nephrology
Baxduo PACIFIC
A phase III, randomized, double-blind, placebo-controlled, event-driven study to evaluate the efficacy, safety, and tolerability of Baxdrostat in combination with dapagliflozin compared to dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and elevated blood pressure
POSIBIL_ESKD
A phase 2b/3, multicenter, randomized, double-blind, placebo-controlled, combined dose-determination and cardiovascular outcomes study to investigate the efficacy and safety of CSL300 (clazakizumab) in end-stage renal disease subjects on dialysis
Completed Studies - Nephrology
BAXDUO Arctic
D6972C00003
"Un estudio de fase III, aleatorizado, doble ciego y controlado de forma activa para evaluar la eficacia, seguridad y tolerabilidad de baxdrostat en combinación con dapagliflozina en comparación con dapagliflozina sola sobre la progresión de la enfermedad renal crónica (ERC) en participantes con ERC y presión arterial alta"
NN9388-7700
Eficacia y seguridad de cagrilintida s.c. coadministrada. 2,4 mg en combinación con semaglutida s.c. 2,4 mg (CagriSema s.c. 2,4 mg/2,4 mg) una vez a la semana en comparación con semaglutida, cagrilinitida y placebo en personas con enfermedad renal crónica y diabetes tipo 2
ZENITH
Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria
ZENITH HP /D4325C00007
Study for the Identification and Characterization of Patients with Chronic Kidney Disease and Proteinuria.
BGB-3111-309
BGB-3111-309: un estudio de fase 3, multicéntrico, aleatorizado, con control activo y abierto para Evaluar la eficacia y seguridad de zanubrutinib en pacientes con membrana primaria Nefropatía. Protocolo de estudio, Versión de enero de 2022.
STABILIZE
To evaluate the effect of sodium zirconium cyclosilicate on the progression of chronic kidney disease (CKD) in participants with CKD and hyperkalemia or at risk of hyperkalemia (STABILIZE-CKD)
BI 1378-0005
Randomized, double-blind, placebo-controlled, twelve parallel group study to investigate the efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetes and non-diabetic chronic kidney disease
6 + 5
FLAIR
Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multi-Dose Study of AZD5718 in Participants With Chronic Proteinuric Kidney Disease
Lipids
Active Studies - Lipids
There are no active studies at this time
Completed Studies - Lipids
PROMINENT
“PROMINENT Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes”
Cardiology
Active Studies - Cardiology
J2O-MC-EKBG
Phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of Muvalaplin on reducing major adverse cardiovascular events in adults with elevated lipoprotein(a) who have had a previous atherosclerotic cardiovascular event or are at risk of suffering a first atherosclerotic cardiovascular event - MOVE-Lp(a)
EASi-HF Reduced
Protocol Title: EASi-HF Reduced: A Phase III, Double-Blind, Randomized, Parallel-Group Superiority Trial to Evaluate the Efficacy and Safety of Combined Use of Oral BI 690517 and Empagliflozin Compared to Placebo and Empagliflozin in Participants with Symptomatic Chronic Heart Failure (CI: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40%
EASi-HF
“A parallel-group, randomized, double-blind, phase III superiority trial to evaluate the efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared to placebo and empagliflozin in patients with heart failure (HF) classes II to IV) and left ventricular ejection fraction (LVEF) ≥40%.”
Completed Studies - Cardiology
BaxHTN
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Baxdrostat in participants with uncontrolled hypertension taking two or more medications, including participants with resistant hypertension.
LIBREXIA ACS
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Based Study to Demonstrate the Efficacy and Safety of an Oral Factor XIa Inhibitor, Following Recent Acute Coronary Syndrome (ACS)
HERMES
Effects of ziltivekimab versus placebo on morbidity and mortality in patients with chronic heart failure with preserved ejection fraction and systemic inflammation.
LIBREXIA AFL
A Phase 3, randomized, double-blind, double-dummy, parallel-group, active study to evaluate the efficacy and safety of Milvexian, an oral factor XIa Inhibitor, versus apixaban in participants with atrial fibrillation.
AMETHYST
AMETHYST - D5496C00005
"A Phase 2, multicenter, double-blind, 3-arm, placebo- and active-controlled study to evaluate the efficacy and safety of Verinurad combined with allopurinol in heart failure with preserved ejection fraction."
NODE-303
Multicenter, multinational, open-label study to evaluate the safety of etripamil nasal spray in patients with paroxysmal supraventricular tachycardia. Phase III
AUGUSTUS
CV185316 Open-label, 2x2 factorial, randomized, controlled clinical trial to evaluate the safety of Apixaban compared to a vitamin K antagonist and aspirin compared to aspirin placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention.
Hepatology
Active Studies - Hepatology
There are no active studies at this time
Completed Studies - Hepatology
FORTUNA
Phase IIb/III, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis.
K-001-201
"Estudio de fase 2, multicéntrico, controlado con placebo, aleatorizado, doble ciego, de 48 semanas para evaluar la eficacia y seguridad de la terapia combinada de K-877-ER y CSG452 en pacientes con esteatohepatitis no alcohólica no cirrótica (NASH) con fibrosis hepática"
Gynecology
Active Studies - Gynecology
There are no active studies at this time
Completed Studies - Gynecology
ESTETRA
MIT-Do001-C301: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort I Study)
Gastroenterology
Estudios Activos - Gastroenterología
There are no active studies at this time
Completed Studies - Gastroenterology
MK 7240-001
Programa de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de MK-7240 en participantes con colitis ulcerosa activa de moderada a grave
LIBERTY
“Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad del tratamiento con dupilumab en pacientes con colitis ulcerosa activa de moderada a severa con fenotipo eosinofílico”
AMG 592 20210210
A Phase 2 Long-Term Extension (LTE) Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
DUET-UC
Estudio de fase 2b aleatorizado, doble ciego, con control activo, de grupos paralelos y multicéntrico para evaluar la eficacia y la seguridad de la terapia combinada de inducción y mantenimiento con guselkumab y golimumab en participantes con colitis ulcerosa activa de moderada a grave.
ASTRO
Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of subcutaneous induction treatment with Guselkumab in participants with moderately to severely active ulcerative colitis.
CC-93538-EE-02
“Estudio de extensión de fase 3, multicéntrico, multinacional, abierto, para evaluar la seguridad a largo plazo de CC-93538 en sujetos adultos y adolescentes con esofagitis eosinifílica”
AMG592 20170104
A Phase 2, dose-finding, randomized, double-blind, placebo-controlled, multicenter study. To evaluate the safety and efficacy of Efavaleukin alfa in induction therapy in participants with moderately to severely active ulcerative colitis
QUASAR
Ulcerative colitis
RLM-MD-04
RLM-MD-04
“52-week, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis”
RLM-MD-03
RLM-MD-03
“46-week, double-blind, placebo-controlled, phase 3 study, with a 6-week randomized drug withdrawal period, to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis”
Endocrinology
Estudios Activos - Endocrinología
HICKORY
ALXN1850-HPP-301
“A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneously administered ALXN1850 (Recombinant Alkaline Phosphatase) in adolescent (12 to <18 years of age) and adult participants with hypophosphatasia who have not been previously treated with Asfotase Alfa.”
MULBERRY
ALXN1850-HPP-305
“Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ALXN1850 vs. Subcutaneous Placebo Administration in Treatment-Negative Pediatric Participants (2 to <12 Years of Age) with Hypophosphatasia (HPP)”
CHESTNUT
ALXN1850-HPP-303
A Phase 3, Randomized, Open-Label, Parallel-Group, Actively Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1850 Compared to Subcutaneously Administered Asfotase Alfa in Pediatric Participants (2 to <12 Years of Age) with Hypophosphatasia (HPP) Previously Treated with Asfotase Alfa
Estudios Finalizados - Endocrinología
No hay estudios finalizados en este momento
Diabetes
Active Studies - Diabetes
kaiNETIC-2
Protocol Number K9531-3104
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Once-Weekly KAI-9531 in Participants with Diabetes Who Are Obese or Overweight.
EFC18241
A phase 3, randomized, double-blind, 2-arm study to investigate the efficacy and safety of teplizumab compared to placebo in participants aged 1 to 25 years with newly diagnosed stage 3 type 1 diabetes (T1D)
Completed Studies - Diabetes
SURPASS-T1D-1
I8F-MC-GPJA: Estudio Fase III, multicéntrico, aleatorizado, doble ciego, controlado por placebo, de grupos paralelos para evaluar la eficacia y seguridad de tirzepatida administrado una vez a la semana en comparación con placebo, en participantes adultos con diabetes tipo 1 y obesidad o sobrepeso (SURPASS-T1D-1).
REIMAGINE 5
NN9388-7741
“Eficacia y seguridad de la administración concomitante de cagrilintida y semaglutida (CagriSema) 1,0 mg/1,0 mg s.c. una vez a la semana en comparación con 5 mg s.c. de tirzepatida una vez a la semana en participantes con diabetes tipo 2 controlados inadecuadamente con metformina, inhibidor de SGLT2 o ambos (REIMAGINE 5)”
TRANSCEND-T2D-3
“Estudio en Fase III, aleatorizado, multicéntrico y doble ciego para investigar la eficacia y seguridad de retatrutida administrada una vez a la semana en comparación con placebo en participantes adultos con diabetes tipo 2, insuficiencia renal moderada o grave con control glucémico inadecuado en la insulina basal con o sin metformina y/o inhibidor de SGLT2 (TRANSCEND-T2D-3).”
ACHIEVE-3
J2A-MC-GZGU A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Oral LY3502970 Once Daily Compared to Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
MK 0431-848
MK0431-848
“Un estudio clínico de Fase III, multicéntrico, randomizado, en doble ciego, controlado con placebo para estudiar la seguridad y eficacia de la adición de Sitagliptina durante el aumento de la dosis de Metformina en comparación con el aumento de la dosis de Metformina sola en participantes con Diabetes Mellitus Tipo 2”
MK 0431-845
MK0431-845
Phase III, multicenter, randomized, double-blind, placebo-controlled clinical study to study the efficacy and safety of continued administration of sitagliptin compared to withdrawal of sitagliptin during initiation and titration of insulin glargine (LANTUS®) in participants with type 2 diabetes mellitus
MK 8835-001
MK 8835-001
“Phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus with stage 3 chronic kidney disease, “whose glycemic control is inadequate with basic antihyperglycemic treatment”
DIA 4003
Protocol 28431754DIA4003
“Randomized, multicenter, double-blind, parallel, placebo-controlled study of the effects of canagliflozin on renal endpoints in adult subjects with type 2 diabetes mellitus.”
Dermatology
Active Studies - Dermatology
INCB 18424-309
Phase 3, randomized, double-blind study on the efficacy and safety of ruxolitinib cream
in children (ages ≥ 6 years to < 12 years) with non-segmental vitiligo.
Completed Studies - Dermatology
INCB 54707-305
Un estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de eficacia y seguridad de Povorcitiniv en participantes con prurigo nodularis
PSO3001
Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of JNJ-77242113 in the treatment of participants with moderate to severe plaque psoriasis, with randomized withdrawal and retreatment
1368-0098
Randomized, double-blind, placebo-controlled, phase IIb/phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa
INCB 18424-319
Phase III, double-blind, randomized, vehicle-controlled study to evaluate the efficacy and safety of ruxolitinib cream in participants with prurigo nodularis; Topical evaluation of ruxolitinib in nodular prurigo (TRuE-PN1)
Cardiometabolico
Estudios Activos - Cardiometabolico
ATTAIN
Protocol title: A phase 3, randomized, double-blind, placebo-controlled, event-based study to investigate the effect of orforglipron on the incidence of major adverse cardiovascular events in participants with established atherosclerotic cardiovascular disease or chronic kidney disease (ATTAIN-Outcomes)
Enith 2
WC45726 (0165/1298):
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL CLUSTER STUDY
CLUSTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF WEEKLY ADMINISTRATION OF RO7795068 (CT-388) TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES.
MARITIME – CV
A phase 3, randomized, double-blind, placebo-controlled study to evaluate the impact of Maridebart Cafraglutide on cardiovascular outcomes in participants living with overweight or obesity and atherosclerotic cardiovascular disease.
BaxDuo PREVENT HF
Phase III study to investigate the risk of heart failure and cardiovascular death with Baxdrostat in combination with dapagliflozin in participants at increased risk of developing heart failure.
BalanceD-HF
"A phase III, randomized, double-blind study to evaluate the effect of balcinrenone/dapagliflozin, compared with dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired renal function (BalanceD-HF)"
Estudios Finalizados - Cardiometabolico
AZURE-LDL
Un Estudio de Fase III, Aleatorizado, Doble Ciego, Controlado con placebo y de Grupos Paralelos para Evaluar el Efecto de AZD0780 sobre el Colesterol de las Lipoproteínas de Baja Densidad en pacientes con niveles elevados de colesterol de las lipoproteínas de baja densidad y Enfermedad Cardiovascular Aterosclerótica Clínica o en riesgo de padecer un primer Evento de Enfermedad Cardiovascular Aterosclerótica.
ACCLAIM-Lp(a) – J3L-MC-EZEF
Un estudio de Fase 3, randomizado, doble ciego, controlado con placebo para investigar el efecto de Lepodisirán en la reducción de eventos adversos cardiovasculares mayores en adultos con lipoproteína(a) elevada, que presentan enfermedad cardiovascular aterosclerótica establecida o corren el riesgo de presentar el primer evento cardiovascular - ACCLAIM-Lp(a)
TRIUMPH
J1I-MC-GZBO
“Estudio en Fase III, aleatorizado, doble ciego, controlado con placebo, basado en eventos para investigar el efecto de la retatrutida sobre la incidencia de los eventos adversos cardiovasculares mayores y el deterioro de la función renal en participantes con un índice de masa corporal >=27 kg/m2 y ateroesclerosis cardiovascular y/o nefropatía crónica."
ZEUS
Research study to see how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease, and inflammation.
DECLARE
Estudio multicéntrico, aleatorizado, doble ciego, controlado con
placebo, para evaluar el efecto de 10 mg de dapagliflozina una vez
al día en la incidencia de muerte cardiovascular, infarto de
miocardio o accidente cerebrovascular isquémico en pacientes con
diabetes tipo 2.
Our Professionals
Authorities
Doctors
Internal Medicine and diabetes
Dr. Alvarisqueta, Andrés Francisco
Dr. Hernández Gauna, Adrián
Dra. Papa, Flavia Susana
Dr. Pereyra, Alejandro Julio
Dra. Reig, Moira Alejandra
Dr. Remon, Javier Agustin
Dra. Soler, Mariana
Dr. Suárez, Walter Gabriel
Infectology
Dr. Ferro, Alejandro
Dr. Iriart, Jose
Dra. Hualde, Mariana
Dr. Manzo, Alexis
Dra. Miglioranza, Cristina Ines
Study Coordinators
Alcazar, Ruth
Blanco, Ana
De Gennaro, Jessica
De Gennaro, Natalia Laura
Del Castello, Fiorella
Figueroa, Germana María
Fontan, Sofia
Ginel, Malena
Ojeda, Milagros
Pérez, Eliana Sofía
Regidor, Victoria
Riveros, Carolina
Nursing
Espirometría
Laboratory
Biochemistry
Regulatory - Start Up
Recruitment
Executive Area
Infrastructure
Facilities
- 450 square meters
- 10 Offices
- Box for sample extraction
- Box for ECG performance
- Wardrobe for patients
- Pharmacy with security code, alarm and cold chain
- Calibrated thermometers
- Lockable storage location for files and medical records
- Storage space with security code for returned medication.
- Monitoring room
- Breakfast area for patients
- Protected cardio space
Technology
- Fully computerized center
- Protected digital information
- 24 hour fax with direct line
- Printer with scanner on each floor
- Generator set to ensure cold chain in pharmacy
- Wifi
- 24 hour monitoring
Equipment
- Refrigerators and freezers with calibrated thermometers
- Laminar flow hood Blood pressure monitors
- Roma scales
- 2 Centrifuges
- Incubator
- Electrocardiograph
- Spirometer
- Defibrillator
- Cabinet with basket for pathological waste and periodic withdrawals by Environmental Systems
Our Sponsors
CRO's
